Objectives: The Neuromonics Tinnitus Treatment combines the use of a novel approach to acoustic stimulation with a structured program of counseling and support by a clinician specifically trained in tinnitus rehabilitation. The distinctive acoustic component has been designed to provide stimulation to auditory pathways deprived by hearing loss, engage positively with the limbic system, and allow intermittent, momentary tinnitus perception within a pleasant and relaxing stimulus, thereby facilitating desensitization to the tinnitus signal. The purposes of this study were (1) to demonstrate the efficacy of the treatment, when enhanced with various modifications since previously reported trials and (2) to test the relative clinical effectiveness of two variations of the approach. In the first, intermittent tinnitus perception was facilitated throughout treatment through the use of a stimulus in which intensity peaks allowed the patients' tinnitus perception to be completely covered up, whereas in the intensity troughs their tinnitus was briefly discernible. In the second, subjects experienced little tinnitus perception while listening to the treatment for the first 2 mo, then experienced intermittent perception.
Results: At 2, 4, 6, and 12 mo after commencing treatment, both groups displayed clinically and statistically significant improvements in tinnitus distress, awareness, and minimum masking levels as well as loudness discomfort levels. Improvements increased with time over the first 6 mo of therapy, at which time 91% of all subjects across the two groups reported an improvement in tinnitus disturbance (as measured by the Tinnitus Reaction Ques-tionnaire) of at least 40%, with a mean improvement of 65%. Also, 80% of subjects at 6 mo reported a level of tinnitus disturbance that was no longer clinically significant. There was some indication of a more consistent benefit over 12 mo for the group that was provided initially with a high level of tinnitus interaction; however, inter-group differences were not statistically significant. A relation between reported treatment usage (hours per day) and clinical outcomes was observed, suggesting that a "dosage effect" may apply with the stimulus provided.
Conclusions:
This study found that the Neuromonics Tinnitus Treatment provides rapid and profound improvements to the severity of tinnitus symptoms and their effect on the subject's quality of life. This was a consistent effect, provided by a treatment that subjects reported as being pleasant to use. Both of the stage-based variations of the treatment that were tested in this study were shown to be successful in achieving these outcomes. (Ear & Hearing 2007; 28; 242-259) Tinnitus is a debilitating condition that is widespread yet difficult to successfully treat. Various models for tinnitus pathogenesis, recently reviewed by Tyler (2005) , emphasize the importance of neurological processes in the development of tinnitus that is disturbing for the patient. In particular, they highlight the processes involved in the interpretation of and response to the perception of the tinnitus signal. Although there appears to be growing consensus around the need for a combination of counseling and acoustic therapy in tinnitus treatment (Tyler, 2005) , the tools currently available for clinicians to administer acoustic therapy continue to be limited by a lack of consistent clinical efficacy, efficiency and/or user acceptability.
Hearing aids are a conveniently accessible option for clinicians when faced with a patient with tinnitus. However, there remains little conclusive evidence for their effectiveness from rigorously controlled studies involving patients with tinnitus as their primary concern. Outcomes reported in published studies (e.g., Surr, Montgomery, & Mueller, 1999) have been modest when their clinical significance is considered. Numerous studies have found that the key tinnitus disturbance periods are the quiet times, such as when trying to sleep, concentrate, or relax (Hallam, Jakes & Hinchcliffe, 1998; Tyler & Baker 1983) . Since hearing aids are configured to maximize speech intelligibility through amplification of ambient sound over the speech range, they typically provide little benefit for patients during these quiet times.
Noise generators or tinnitus maskers have been widely recommended for many years. However, a number of studies of their effectiveness as part of tinnitus management programs combining counseling with acoustic therapy (Dineen, Doyle, Bench, et al., 1999; Erlandsson, Ringdahl, Hutchins & Carlsson, 1987; Hiller & Haerkotter, 2005; Jakes, Hallam, McKenna & Hinchcliffe, 1992) have questioned whether the acoustic stimulation they provide yields any material incremental benefit over the counseling component of such programs. Furthermore, there are reports of patient acceptability problems and high return rates with such devices (Henry, Schechter, Nagler, et al., 2002; Hiller & Haerkotter, 2005) .
The Neuromonics Tinnitus Treatment, formerly referred to as the Acoustic Desensitization Protocol (Davis, Wilde & Steed, 2002a; 2002b) , is a newly available approach that incorporates the principles of systematic desensitization (Davis, 2005) . It comprises a 6-month, structured rehabilitation program by audiologists specifically trained in tinnitus treatment. Central to the technique is the home use of an audio recording of a binaurally correlated acoustic signal that intermittently covers up the patient's tinnitus perception. The acoustic signal is highly customized for each individual's hearing and tinnitus characteristics so that it can provide a sense of relief at a comfortable listening level while providing stimulation across a broad frequency range. By using the device (i.e., the acoustic stimulus) at the key distress times, the effects of the tinnitus can be overcome and a sense of control facilitated. In combination with counseling, this helps to reduce the significance of the tinnitus to the patient, with the intended objective of reducing any neurally mediated enhancement of the tinnitus (Jastreboff & Hazell, 1993) . By gradually breaking down the ability to detect the tinnitus, the amount of sound needed to cover up the tinnitus typically reduces over time. Patients correspondingly find that they gradually become less aware of their tinnitus, and less disturbed by it, even while not using the device. Improvements in sound tolerance levels are also commonly found (Davis, 1998) .
Over a period of more than a decade, the Neuromonics Tinnitus Treatment has been the subject of two formal clinical trials prior to the current study. These studies have revealed the approach to be highly effective and efficient relative to available alternatives (Davis & Wilde, 1995; Davis, 1998; Davis, Wilde & Steed, 2001; 2002b) . The second trial in the series explored the relative contributions of the treatment's two key elements, i.e., the customized acoustic stimulus and counseling. It demonstrated that the customized acoustic stimulus generates a material incremental benefit over counseling alone and produces better outcomes than broadband noise provided together with counseling.
The acoustic stimulus used in Neuromonics Tinnitus Treatment has been specifically designed to promote desensitization to the tinnitus perception through a combination of elements:
1. It aims to stimulate auditory pathways across a broad frequency range through the use of a broadband stimulus that is spectrally contoured to account for each individual's hearing profile. This includes hearing thresholds at high frequencies (up to 12.5 kHz), as these have been implicated in the pathogenesis of tinnitus (e.g., Domenech, Fuste, Traserra, et al., 1991; Eggermont, 2005; Norena & Eggermont, 2005) . This customization, which is performed separately for each ear, ensures that a genuinely broad frequency stimulus is delivered to the auditory system at a low overall listening level. This contrasts with broadband noise generators, which in practice provide only a narrow band of effective stimulation, centered around the 0.5 to 2 kHz range, for patients with age-related or noise-induced hearing loss (Baguley, Beynon & Thornton, 1997) . The potential for benefit from the use of a customized acoustic stimulus is supported by recently published animal studies that objectively demonstrated that tonotopic reorganization associated with noise induced high-frequency hearing loss was preventable through administration of an acoustic stimulus specific to the regions of hearing loss (Norena & Eggermont, 2005) .
2. It controls the correlation between the left and right channels. This is done with the intention of promoting stimulation across the auditory integrative pathways in a manner not possible in noise generators, maskers, or hearing aids, which have independent phase relations between the ears.
3. It provides this stimulus in the context of relaxation music, which aims to achieve two objectives. First, it seeks to foster a strong relaxation response. This is consistent with studies of music therapy, supporting the treatment principle that listening to relaxation music can engender a powerful relaxation response (Standley, 1995) , with an effect size that is equivalent to that of progressive muscle relaxation training (Kibler & Rider, 1983; Stoudenmire, 1975) . Second, it makes the therapy pleasant to administer and thereby facilitates compliance to treatment. By customizing the music, patient acceptability is further enhanced, in contrast to many tinnitus patients' attempts at using regular (i.e., non-customized) music. In the authors' experience, such patients commonly report that noncustomized music needs to be turned up to a volume that is uncomfortably loud before it generates any significant interaction with or masking of their tinnitus perception. This is consistent with the mismatch between the low-frequency emphasis of music and the high-frequency bias of the hearing loss commonly found in tinnitus patients (Davis, Wilde & Steed, 2002a) . This mismatch is addressed as part of the Neuromonics customization procedure.
4. In the early stages of treatment, by allowing patients to cover up their tinnitus perception to a high degree, within a pleasant listening experience, it promotes a strong sense of relief and control. This is done with the intention of tempering the limbic systemmediated secondary reaction that is believed to be a major contributor to tinnitus disturbance (Jastreboff & Hazell, 1993) .
5. Through the dynamics of the music, when appropriately customized and delivered in a controlled fashion, it allows the patients to perceive their tinnitus intermittently. It thereby allows momentary and repeated exposure to the tinnitus perception in a strongly relaxationinducing context. In combination with the intensive, collaborative, counseling program, the progressively increasing degree of tinnitus perception facilitates a novel version of "systematic desensitization." A common behavior therapy technique, systematic desensitization uses hierarchies of anxiety provoking situations that are imagined or experienced in reality while a person is in a state of deep relaxation to facilitate desensitization to the anxiety-provoking stimulus (Atkinson, Atkinson & Hilgard, 1983) . In applying these principles to the treatment of tinnitus, in light of the practical challenges observed by others (Tyler, 1996) , relaxation music was incorporated into the Neuromonics Tinnitus Treatment instead of the traditional progressive muscle relaxation training (Davis, 2005) .
The first clinical trial of this approach (Davis & Wilde, 1995) was an initial feasibility study to determine whether this notion of spectrally modifying music would be effective in a randomized, controlled trial environment. It was a paired comparison of spectrally customized music versus spectrally customized noise. Results of this investigation found that the customization process made the stimuli more palatable to patients than the original source recordings, particularly for the group that received customized music. The customized music was found to be more clinically effective than the customized noise on a number of measures. A key post hoc finding of this study was that the patients who did not completely cover up their tinnitus perception all the time had the greatest long-term improvements in tinnitus distress. With this music being a dy-namic stimulus, it was the first indication that an intermittent type of masking effect was occurring while using this unique stimuli.
The second trial (Davis, Wilde & Steed, 2002b ) was a randomized, controlled study that compared the effectiveness of the Neuromonics Tinnitus Treatment relative to a counseling-only control group, as well as a group that received bilateral broadband noise (set at the "mixing point") plus counseling. Two variations of the Neuromonics approach were used, both using customized acoustic stimuli prepared and delivered to patients using analogue sound processing technology. This study revealed superior clinical outcomes for the Neuromonics Tinnitus Treatment groups relative to the other treatments.
It has been the authors' clinical experience that the term "masking" is subject to misinterpretation by patients, whereby they often construe it as an "all or nothing" experience. Such an interpretation is an unhelpful oversimplification of the spectrum of degrees of masking that clients typically experience, even with a simple stimulus such as broadband noise. Furthermore, with a stimulus (such as music) that is dynamic, i.e., that displays variation in intensity over time, the patient's masking experience is also dynamic. When appropriately tailored for the patient's hearing profile and used in a controlled manner, it is possible to achieve an intermittent type of masking effect, whereby the tinnitus perception may be covered up in the intensity peaks of the acoustic envelope, then become momentarily apparent in the intensity troughs. The Neuromonics Tinnitus Treatment incorporates a "self-dosing" protocol whereby patients are instructed to set the volume of their customized acoustic stimulus to a level which they perceive their tinnitus to be covered up approximately 50% of the time, or covered up 100% of the time. After training in this procedure at the device fitting appointment, most clients report that they are able to readily achieve these outcomes at the appropriate times. The administering clinician can cross-check the volumes used by the patient to achieve 100% and 50% interaction through the course of treatment against the levels noted at the beginning of treatment to ensure that the intensity is within the expected range.
The basis for the two-stage protocol explored in the current study lies, in part, in an unexpected discovery after completion of the prior trial. That discovery was that a number of the study's most successful participants had, of their own accord, deviated from the volume setting protocols prescribed for them. These subjects had initially used their spectrally modified acoustic stimuli to cover up their tinnitus perception as completely as possible to gain a greater degree of relief and control. Then, over the following weeks and
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EAR & HEARING / APRIL 2007 months, they tended to spontaneously reduce the stimulus volume to a level that provided more intermittent tinnitus perception. In retrospect, it was realized that these subjects' experience tended to mimic the clinical presentation of patients undergoing systematic desensitization for treatment of phobias, with a relaxation-inducing acoustic signal used in place of progressive muscle relaxation. The adaptation of this model needed clinical verification in a controlled study, where it was deliberately prescribed from the outset. In this present study, the approach was further enhanced by a midtherapy change in the nature of the acoustic stimulus to more effectively facilitate a graded increase in the "noxious stimulus" (in this case, the tinnitus perception) that is a fundamental tenet of the systematic desensitization approach.
This paper concerns the third clinical trial of the Neuromonics Tinnitus Treatment, which had two overarching objectives:
1. To demonstrate the effectiveness of the treatment, when enhanced with various modifications since previously reported trials. In particular, the authors had modified the technique through the application of digital technology to the spectral modification process that customizes the acoustic stimulus for each patient's profile, and in the sound reproduction devices for patient use; 2. To determine which of two variations of the approach is more effective: a one-stage protocol, in which subjects experience intermittent tinnitus perception throughout treatment, and a two-stage protocol, in which the tinnitus perception is covered up to a high degree for an initial 2-mo period (facilitated by the addition of a customized broadband frequency signal to the acoustic stimulus), then the patient experiences intermittent tinnitus perception over a subsequent 4-mo period.
MATERIALS AND METHODS

Study Design
The experimental design was a repeated-measures construction with random allocation into one of two equal sized parallel groups: one-stage (intermittent perception throughout) or two-stage (complete covering of perception initially, then intermittent perception). After initial assessment and instruction in use of the sound player device and the individually customized acoustic stimulus, clinical data were collected at 2, 4, 6, and 12 mo after commencement of treatment.
As the previous study incorporated a counselingonly control group (Davis, Wilde & Steed, 2001;  2002a), it was not considered necessary to repeat such a control group in the current clinical trial. A no-treatment control group was not used on ethical and humanitarian grounds, i.e., subjects with significant tinnitus distress could not be reasonably asked to refrain from any attempts at relief (or treatment) for 1 yr. The experimental design was approved by the Human Research Ethics Committee of Curtin University of Technology's Division of Health Sciences, with approval # HR 117/2002.
Participants
A total of 42 participants were recruited, and the time of their first contact determined the next chronological subject number. They were later randomly allocated between the two groups on the basis of a random number sequence generated using SPSS software.
Referral to the study was from a variety of sources including Ear Nose & Throat (ENT) specialists, other health professionals, a newspaper advertisement, and word of mouth. It is the authors' view that the subject sample was broadly representative of the patients that a typical tinnitus clinic would recommend for a rehabilitation program in terms of their general demographic characteristics and clinical presentation. All subjects had a recent ENT consultation that determined that medical treatment of their tinnitus was not feasible.
Of the 42 subjects recruited, seven were subsequently excluded from analysis because their pretreatment levels of tinnitus-related disturbance were not clinically significant, as determined by a Tinnitus Reaction Questionnaire (TRQ) (Wilson, Henry, Bowen, et al., 1991) score below 17 . Those excluded who had TRQ scores below 17 but reported decreased sound tolerance as their primary concern will be reported separately. Of the 35 remaining subjects, one was lost to follow-up after the 4-mo review; this individual was included in the data analysis on a "last value carried forward" basis. To control for any socioeconomic bias, subjects neither paid for their treatment, nor were they reimbursed for their time and expenses.
Exclusion criteria were as follows: • A significant hearing loss in the speech range, as defined by a four-frequency average hearing threshold level (HTL) (0.5, 1, 2, and 4 kHz) of greater than 50 dB in the best-hearing ear, in light of the challenges associated with the use of an acoustic stimulus for patients with a moderate to severe loss in both ears; • Any ongoing compensation-type claims related to tinnitus, including Department of Veterans' Af-fairs pension, or sickness benefit applications, as this is a variable that has been found to influence the level of response reliability (Davis, Wilde, & Steed, 1999) ; • Clinically significant psychosis, depression, cognitive incapacity, or insufficient English language abilities to reliably perform the test measures;
• A level of tinnitus-related disturbance not clinically significant (as indicated by TRQ score below 17); • Maintenance of any significant factors that caused tinnitus to emerge or be aggravated, such as loud noise exposure, ototoxic medication, disease process;
• Concurrent treatment of tinnitus (including recent onset of hearing aid usage exceeding one hour per day); two long-term users of hearing aids were recruited to the study, one per treatment group.
The two-stage group comprised 19 subjects whose pretreatment level of tinnitus-related disturbance was clinically significant, whereas the one-stage group comprised 16 subjects. The gender mix across the two groups was 74% male and 26% female (31% female in the one-stage group, 21% in the two-stage group). There was a mean age across the two groups of 58.5 yr (standard deviation [SD] ϭ 13.4), with a range of 22 to 87 yr (one-stage: mean, 61.3; SD, 8.9; range, 45 to 75 yr; two-stage: mean, 56.1; SD, 16.2; range, 22 to 87 yr). The mean duration since tinnitus was first noticed was 11.0 yr (SD ϭ 11.3) (one-stage: mean, 13.0; SD, 12.8; two-stage: mean, 9.2; SD, 9.9), whereas the mean duration from when subjects reported that their tinnitus had become disturbing was 5.9 yr (SD ϭ 5.5) (one-stage: mean, 6.2; SD, 5.4; two-stage: mean, 5.7; SD, 5.7). Twenty-six subjects (74%) also reported the presence of decreased sound tolerance in their written history questionnaire.
The mean TRQ score across the two groups was 35.5 (SD ϭ 14.4), with a range of 17 to 67 (one-stage: mean, 33.4; SD, 13.9; range, 17 to 63; two-stage: mean, 37.4; SD, 15.0; range, 19 to 67). These mean levels correspond with a moderate level of severity, relative to the normative data collated by the TRQ's authors, in which the 50th, 75th, 90th, and 95th percentiles of a diverse population of 156 tinnitus clinic patients were represented by TRQ scores of 27, 47, 60, and 72, respectively (Wilson, Henry, Bowen, et al., 1991) . The mean pretreatment TRQ (at 35.5) is in line with that reported in another study which drew on a large clinic sample of 165 distressed tinnitus patients, in which subjects were selected on the basis of having at least a moderate degree of tinnitus-related distress as indicated by a TRQ score of 17 or greater (Henry & Wilson, 1999) .
To facilitate comparison between the patient population reported in this study with other populations assessed using another widely accepted measurement tool, the Tinnitus Handicap Inventory (THI) (Newman, Jacobson, & Spitzer, 1996) , we have determined an approximate transform function, based on a sample of 135 tinnitus patients assessed simultaneously with both TRQ and THI (Tyler, personal communication, March 2006) . Based on that population, using constrained linear regression analysis (e.g., Greene, 2003) , a quadratic predicted transform function was estimated. This method was used to compel the estimated equation to pass through points (TRQ ϭ 0, THI ϭ 0) and (TRQ ϭ 104, THI ϭ 100), which reflects the reality that the two indexes must be the equal at those two points. A quadratic (in TRQ) regression model was used in order to reflect the apparent non-linear nature of the relation between the two indexes. The resulting equation is THI ϭ 1.591 * TRQ -0.00605 * TRQ 2 , where TRQ and THI were scores on the TRQ and THI, respectively, before treatment. Applying that transform to this patient population, the mean TRQ of 35.5 would predict a mean THI of 48.8 (95% confidence interval for mean: 46.6 to 51.1). On this basis, the mean degree of tinnitus disturbance before treatment appears comparable with that reported in the population that was the subject of the recent study comparing Tinnitus Retraining Therapy (TRT) with Tinnitus Masking therapy (Henry, Schechter, Loovis, et al., 2005) . Figure 1 illustrates the mean level of hearing loss among the subjects. This was consistent with the commonly encountered tinnitus clinic patient profile (Henry, Meikle & Gilbert, 1999; Jastreboff, Sheldrake & Jastreboff, 1999) , whereby hearing is normal for the low to mid frequencies, displays a mild loss for only the highest part of the speech range, and includes significant loss in the very high frequencies.
Only one of the 35 subjects had normal hearing (HTL of 20dB or less) at all frequencies, and four were clear hearing aid candidates, again consistent with comparable tinnitus clinic populations, where only 20 to 30% of subjects were hearing aid candidates (McKinney, 1999; Sheldrake, Hazell & Graham, 1999) . Differences in mean hearing thresholds were evident between the two treatment groups, and were statistically significant ( 2 8 ϭ 17.41, p ϭ 0.026). The average difference between groups, at 4 dB across all frequencies and 7 dB across frequencies below 4 kHz, was modest relative to the overall variability between subjects (1 standard deviation corresponding to 17 dB for the one-stage group and 20 dB for the two-stage group) and so is not considered to be functionally significant, particularly in the context of provision of an acoustic stimulus which is customized to account for variations in hearing thresholds.
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Acoustic Stimulus
The acoustic stimulus used in present study was created by combining a selection of commercially available music recordings with a specially designed broad frequency noise component (commonly described by patients as being perceptually similar to a shower sound) at a predetermined signal-to-noise ratio and then individually customizing this mixture by spectral modification using proprietary, patented digital sound processing algorithms (Davis, 2004; Davis, 2005) . The initial music selection was chosen on the basis of a suite of characteristics intended to facilitate a positive relaxation response, including a tempo consistent with the normal, relaxed heart beat of 60 to 80 beats per minute. The addition of the tailored noise component, which is specific to the first stage of the two-stage treatment protocol, is intended to fill in the intensity troughs in the customized music, thereby allowing greater relief from tinnitus at a low listening volume in the early stages of treatment, as illustrated schematically in Figure 2 . The digital sound processing algorithms reshape the music/noise combination so as to account separately for each individual ear's audiometric profile, then combined in a manner that accounts for any asymmetry in hearing thresholds across the two ears and provides the acoustic stimulus in stereo. The customization process boosts intensity in areas where an individual has relatively poorer hearing, and reduces the intensity in areas of relatively stronger hearing. It also takes into account the abnormally low loudness tolerance levels often displayed by tinnitus patients (Stouffer & Tyler, 1990) .
Two subjects who had one ear with a severe to profound hearing loss across the speech range were fitted with a contralateral protocol, whereby the stimulus was provided through the better hearing ear.
Measurement Devices
The TRQ was the principal measurement instrument in the previous clinical studies of the Neuromonics Tinnitus Treatment, and so was retained for the present study. This measurement tool was chosen because of its well-established and robust psychometric properties including its test-retest reliability, construct validity, and internal consistency (Wilson, Henry, Bowen, et al., 1991) . The TRQ directly summates the degree of tinnitus distress over 26 items that are indicative of the extent of lifestyle disturbance. It yields a composite score with a maximum possible distress level of 104.
In analysis of TRQ results, a threshold for a clinically significant improvement was set, at 40% of pretreatment TRQ. This is intended as the minimum level above which the observed improvement can reasonably be expected to be apparent to the subject. Other researchers have previously defined this threshold in relation to responses to tinnitus treatment as either a minimum of 20% (Hiller & Haerkotter, 2005) , 30% (Jastreboff, 1996; Nagler, 1998) or 40% improvement (Hazell, 1999; McKinney, Hazell & Graham, 1999b) . The more conservative 40% threshold was adopted for the present study as it was more likely to ensure that a change was more clearly evident from the patients' perspective.
Following the method of Coles (1991) , visual analogue scales were used to quantify tinnitus severity, general relaxation levels and loudness sensitivity. They were pretherapy anchored at 5, with an improvement toward 0 and deterioration toward 10, i.e., "assume that your general level of relaxation at the start of program was 5. Now, please grade your general level of relaxation as it now seems, with improvement towards 0, and worsening towards 10." Although these measures are entirely subjective, it may be argued that the clinical problem is the individual's subjective response to their tinnitus (or decreased sound tolerance), and so a measure that reflects the patient's perspective can thus have considerable clinical validity.
The TRQ and visual analog scales were pen-andpaper tests that each subject completed with reference to the effects of the tinnitus in the week before each clinic visit. The forms were dispensed by the clinic administrator and the subjects completed them unassisted so that they could not be subject to any experimenter bias.
Objective audiological measures were performed in a standard sound-attenuating booth, using a Maico MA53 audiometer and Sennheiser HDA200 headphones. The 10 and 12.5 kHz dB HL values were calibrated according to ISO TR/389-5. Psychoacoustic measurement of tinnitus characteristics were performed using procedures based on the Oregon Health Sciences University Tinnitus Clinic protocol (Vernon & Meikle, 1988) . Tinnitus pitch matching was performed using the two-alternative forced choice procedure. The Minimum Masking Level (MML) procedure is a widely used index of tinnitus change (Jastreboff, Hazell, & Graham, 1994) . In theory, it also has potential as an index of how readily a patient's tinnitus can functionally be masked by environmental sounds. It was determined by initially measuring the patient's hearing threshold with broadband noise, and then increasing the noise intensity to the point where it just fully masked perception of the tinnitus. A sensation level value was determined by subtracting the hearing threshold from the masking level.
Loudness Discomfort Levels (LDLs) are an index of the patient's tolerance of louder sounds. LDLs are frequently quite reduced in tinnitus patients and are considered to reflect how much "central auditory gain" is present in an individual (Hazell, Sheldrake & Graham, 2002) . They were measured with pure tones at 0.5, 1, 2, 4, and 6 kHz in each ear. The technique of Hawkins et al. (Hawkins, Walden, Montgomery, et al., 1987) was used, whereby subjects were instructed to point to the phrase on the list that described how loud each level of sound appeared to them. Response options on the ninepoint ascending scale were; very soft, soft, comfortable but slightly soft, comfortable, comfortable but slightly loud, loud but OK, uncomfortably loud, extremely uncomfortable, painfully loud. The tones were slowly and consistently increased in 5 dB steps until the patient indicated that it had become uncomfortably loud, then the level was dropped 10 dB, then increased again in 2 dB steps until the uncomfortably loud level was determined. It was adapted for safe use in the tinnitus clinic by asking subjects to estimate how loud each level of sound would be if they had to listen to it for more than a minute. Actual presentation time was more fleeting, to prevent any exacerbation of tinnitus. As a result, this approach can be expected to provide values somewhat lower than absolute LDLs or LDLs measured using other methodologies. However, it is no less appropriate for measuring changes with therapy since the same procedure was used before and after therapy.
To quantify the degree of benefit from the individualization process, a comparison was made for each subject between the acoustic output of their customized stimulus and that of the non-customized version of the same stimulus. At the fitting session, using the customized and non-customized stimuli in turn, participants were asked to slowly increase the volume of their device to the point at which they could just no longer perceive their tinnitus (i.e., their "Stimulus Masking Level"). The program was returned to the beginning, and output from the headphone jack plugged directly into the pre-amplifier of a real-time Bruel & Kjaer Sound Level Analyser (Type 2146) via a single stereo to dual RCA plugs, using the plug corresponding to the output from the worst tinnitus ear. A 64-second averaged recording of the peak spectral intensity of the stimulus at the individual's Stimulus Masking Level was then measured, with values expressed using the dBA scale, as appropriate for such a complex, dynamic stimulus. This procedure was then repeated with instructions to set the volume at a level that covered up their tinnitus 50% of the time, again using the customized and non-customized stimuli in turn.
At 12 mo, a Treatment Completion Survey was administered. Subjects were asked to rate the degree of benefit they perceived on eight different aspects of their tinnitus experience and general well
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EAR & HEARING / APRIL 2007 being. On each dimension, they were asked to indicate the degree of benefit by marking the correct response from a four-point scale: 0 (not at all), 1 (to a small degree), 2 (to a moderate degree), or 3 (to a large degree), e.g., "Do you now feel that the Neuromonics Tinnitus Treatment has reduced the degree to which you are disturbed by your tinnitus?" In addition, subjects were asked whether they found the treatment pleasant to listen to, and whether they would recommend the treatment to others, by indicating "yes" or "no."
Audiological Staff
In addition to the primary researcher, 10 final-year Master of Audiology students also collected clinical data for the study as part of their training in Complex Adult Rehabilitative Audiology. A clinical script was followed to ensure equal treatment of each patient, and this was supported by the use of multimedia tools to educate subjects on tinnitus pathogenesis.
Clinical Procedure
The clinical sessions for both groups proceeded as follows:
1. Pre-therapy evaluation: the baseline audiological testing was performed, including Very High Frequency Audiometry (10 and 12.5 kHz), MML, LDL, as well as TRQ. Counseling was provided regarding their tinnitus and their neurophysiological/cognitive response to it (Davis, 2005) . 2. Fitting appointment (approximately 1 week after pretherapy evaluation): each subject was dispensed with a high-fidelity personal sound player and earphones, along with their customized acoustic stimulus, and given appropriate instruction in their use. Sound Level Analyzer measures were made of Stimulus Masking Levels using customized and matched non-customized stimuli. Reinforcement counseling was provided as to the underlying rationale for use of the stimuli (Davis, 2005) , and further discussion time about tinnitus was allowed. 3. Two-week post-fitting review: review of progress and answering of any questions that had arisen, and identification of any cognitive distortions that may be interfering with desensitization to the subject's tinnitus. 4. Two-month post-fitting review: repeat of outcomes measures, additional counseling, and provision of second stage stimuli (for intermittent interaction) to subjects in two-stage treatment group. 5. Four-month post-fitting review: repeat measures of MML, LDL, and TRQ. 6. Six-month post-fitting review: repeat measures of MML, LDL, and TRQ.
7. Twelve-month post-fitting review: repeat measures of MML, LDL, and TRQ, plus Treatment Completion Survey.
Statistical Analysis
Statistical methods consisted of descriptive statistics for all outcomes and inference using methods appropriate for the features of the data and for the required analyses. A salient feature of many of the variables is the repeated nature of measurements. Consequently, due care was devoted to choosing methods that account for this feature at all times. For example, if a t-test was chosen to compare means between two time points, a paired t-test was used. For continuous outcomes, t-tests were performed for two-group comparisons and (repeated-measures) ANOVA was used for more than two. ANCOVA was used when required to test the effect of continuous variables on outcomes at specific time points. When these were not significant, the model simplified to the more usual ANOVA setting. In view of a possible lack of normality, inferential analyses of outcomes were conducted on transformed variables, specifically square-root and (natural) logarithm, as well as on the original scale.
To determine when results on a transformed scale were preferred, the Shapiro-Wilk test of normality (Shapiro and Wilk, 1965) was used. In cases where only a slight lack of normality was detected, robust standard errors were used to make inferences about the original variable more conservative, and the results on the original scale were preferred. As a result of this approach, it was considered that all results for the transformed data were sufficiently similar to those on the original scale, so results discussed below are for the latter. Complex multiple regression models, such as ANCOVA models, were simplified using a backward, stepwise regression approach (e.g., Draper & Smith, 1998 ) with a 5% significance criterion. Starting from a maximal model which included all appropriate predictor variables and corresponding first-order statistical interaction terms, this approach was used to obtain the simplest model including only significant predictors. Most often, only changes over time remained in the simplest model. z-tests or Wald tests (multivariate z-tests) were used to determine significance, or otherwise, of regression coefficients in regression models. Chi-squared tests, logistic, and multinomial-logistic regression analyses were used for discrete outcomes. Descriptive statistics were compiled using Excel 2002 and inferential analyses were conducted by using STATA (v 9.2; 2005) .
RESULTS
Daily Device Usage
Subjects were instructed to use the treatment for 2 hr or more per day, particularly at those times of the day when their tinnitus was most disturbing. Figure 3 shows the mean reported daily usage of the device for the two groups at the 2-, 4-, 6-, and 12-month review points. Broadly consistent with instructions as to usage, initial mean usage was just over 2 hr per day, gradually reducing over the course of treatment to a mean of 1.2 hr usage per day. This reduction in reported treatment usage was statistically significant across the two groups over the course of treatment ( 2 3 ϭ 26.92, p Ͻ 0.001). Differences between treatment groups were not significant, either at the global level ( 2 1 ϭ 0.09, p ϭ 0.760) or for any individual time interval.
Impact of Customization on Listening Volume and Stimulus Masking Levels
The mean minimum listening volume at which the stimulus completely covered up each individual's tinnitus perception (which we refer to herein as the Stimulus Masking Level) was measured at the time of fitting with both customized and non-customized stimuli. The group means of these measurements are displayed in Figure 4 . Repeated-measures ANOVA analysis reveals significant differences in mean Stimulus Masking Level between customized and non-customized stimuli, which is greater for the two-stage group (mean difference, -16.11; z ϭ -10.41; p Ͻ 0.001) than the one-stage group (mean difference, -10.53; z ϭ -5.17; p Ͻ 0.001); the variation in the size of the difference was significant between the treatment groups (z ϭ 2.21, p Ͻ 0.027).
This illustrates that the customization process was able to greatly reduce the intensity level required to fully cover up the tinnitus perception for both groups and that the two-stage group's stimulus (which has additional customized noise added to it) was more effective in this regard. With the twostage group stimulus, customization allowed tinnitus perception to be covered up with a listening volume that was on average 16 dB lower than the non-customized stimulus.
Tinnitus Reaction Questionnaire
The group mean TRQ scores over treatment are displayed in Figure 5 , indicating that over the first 2 mo, there was a very large drop in the mean level of Fig. 3. Device usage (hours per day) reported by subjects in each group. Solid bars represent group means, with error bars corresponding to 1 standard deviation. 
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There was a statistically significant improvement in TRQ scores across both groups from pretreatment to 2 mo (repeated measures ANOVA: z ϭ -10.55, p Ͻ 0.001) and to the later time points (4 mo: z ϭ -11.73, p Ͻ 0.001; 6 mo: z ϭ -11.49, p Ͻ 0.001; 12 mo: z ϭ -12.37, p Ͻ 0.001). Inter-group differences were not statistically significant (p ϭ 0.642). From 2 to 12 mo, 26 of the 35 subjects reported further improvement; however, the improvements over this period were not statistically significant (Wald test for equality of differences from pretreatment to each other time point: 2 3 ϭ 3.75, p ϭ 0.290). Differences from 2 to 4 and 6 mo were not significant (z tests: p ϭ 0.238 and p ϭ 0.301, respectively), and from 2 to 12 mo was trending toward significance (p ϭ 0.056). A deterioration (i.e., increase) in mean TRQ score for patients in the one-stage group is apparent; since the majority of subjects displayed further improvement or no change between 6 and 12 mo, the data do not suggest a systematic deterioration between 6 and 12 mo. The difference between the two treatment groups was not significant across any of the time points.
The proportions of each group displaying a clinically significant improvement (taken as a reduction of at least 40%) are displayed in Figure 6 . This shows that both groups had high numbers of participants who achieved that benchmark: at 6 mo, 91% of all subjects had achieved this benchmark. The two-stage group ultimately displayed the most consistent improvement: at 12 mo, 89% of subjects in the two-stage group had an improvement in TRQ score of at least 40%, compared with 75% for the one-stage group. Note that this last figure reflects a small increase in mean TRQ from 6 to 12 mo in the one-stage group, as discussed above.
For the 40% improvement criterion, differences between treatment groups across all time intervals were not significant (repeated measures ANOVA: p ϭ 0.695). There are significant differences between time intervals (Wald test for differences between intervals: 2 3 ϭ 8.37, p ϭ 0.039). However, after month 2, these differences are not statistically significant across both treatment groups (p ϭ 0.141), or separately for each treatment group. Individual outcomes from treatment (for both treatment groups) are displayed in Figure 7 . It shows that many individuals had very large improvements in their levels of disturbance, and that this was the case for individuals with a wide range of pretreatment TRQ scores.
Statistical analysis revealed no correlation (or inverse correlation) between pretreatment TRQ score and degree of improvement with treatment. Furthermore, after dividing the pooled subjects into two groups consisting of the 18 "most severe" and the 17 "least severe" according to pretreatment TRQ, statistical analysis revealed no significant difference between the two severity groups in terms of the changes in TRQ with treatment to any time point (repeatedmeasures ANOVA: z ϭ 0.54, p ϭ 0.586).
After 6 mo of treatment, 80% of all subjects across the two groups reported a level of tinnitus disturbance that was no longer clinically significant (as measured by a TRQ score below 17). These benefits were largely sustained at 12 mo, with 77% of subjects reporting a TRQ below 17 (75% for the onestage group, 79% for the two-stage group). Figure 8 displays the mean percentage of the time that subjects reported having been aware of their tinnitus over the previous week. This showed a trend in both groups whereby the awareness approximately halved over the first 2 mo of treatment. Further improvements were more gradual over the remainder of the treatment program. At 12 mo, mean tinnitus awareness was 37% for the one-stage group and 32% for the two-stage group.
Tinnitus Awareness
Repeated-measures ANOVA analysis indicates that the reductions in the level of awareness were significant across the two groups from pretreatment to 2 mo, (z ϭ 9.1, p Ͻ 0.001) and to the later time points [4 mo (z ϭ 10.99, p Ͻ 0.001); 6 mo (z ϭ 10.24, p Ͻ 0.001); 12 mo (z ϭ 11.35, p Ͻ 0.001)]. Although Fig. 7 . Individual outcomes from treatment, expressed relative to their level of disturbance at pretherapy. Each individual is plotted according to their level of disturbance (TRQ score) before treatment (horizontal axis) and their degree of improvement in disturbance (TRQ score reduction, expressed as a percentage of pretreatment TRQ score, vertical axis). 
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EAR & HEARING / APRIL 2007 the difference between 2 and 4 mo is not significant (p ϭ 0104), the differences between 2 and 6 (p ϭ 0.004) and 2 and 12 mo (p ϭ 0.016) were clearly significant. Differences between treatment groups were not significant across time intervals (p ϭ 0.785).
In terms of clinical significance, at 6 mo, 86% of subjects across the two groups reported a reduction in their tinnitus awareness of at least 40%; this comprised 88% of subjects in the one-stage group and 84% of those in the two-stage group.
Visual Analogue Scales
Visual analogue scale scores, expressed as group means (and standard deviations), are displayed in Table 1 for three different dimensions: 1, tinnitus severity (in terms of how much it affects subject's lifestyle); 2, general level of relaxation; and 3, sensitivity to loud sounds. In all cases, mean scores for both groups display large improvements at 2 mo, which are then followed by more modest additional gains thereafter. Lower means and smaller standard deviations in the two-stage group at 12 mo, indicate more consistent improvements in that group relative to the one-stage group.
In relation to scores for tinnitus severity, repeated-measures ANOVA analysis indicated that there was a significant difference across both groups from pretreatment to 2 mo, (z ϭ 9.78, p Ͻ 0.001) and to the later time points [4 mo (z ϭ 7.83, p Ͻ 0.001); 6 mo (z ϭ 6.91, p Ͻ 0.001); 12 mo (z ϭ 8.09, p Ͻ 0.001)]. Further analysis indicated that the gains were greatest in the early months. Gains were statistically significant from 2 mo to 4 mo, ( 2 1 ϭ 6.4, p ϭ 0.011), from 2 to 6 mo ( 2 1 ϭ 13.9, p ϭ 0.0002), and from 2 to 12 mo 2 1 ϭ 4.82, p ϭ .028). Intertreatment group differences were not statistically significant.
For general level of relaxation, there was a significant difference across both groups from pretreatment to 2 mo (repeated-measures ANOVA: z ϭ 8.64, p Ͻ 0.001), but changes after that were not signifi-cant ( 2 3 ϭ 6.44, p ϭ 0.092). However, the difference between 2 and 6 mo was significant ( 2 1 ϭ 5.97, p ϭ 0.015). Inter-treatment group differences were not statistically significant.
For sensitivity to loud sounds, changes were significant across both groups at 2 mo (repeated-measures ANOVA: z ϭ 10.21, p Ͻ 0.001). After 2 mo, the overall difference was not significant ( 2 3 ϭ 7.3, p ϭ 0.062). However, the difference between 2 and 6 mo was significant ( 2 1 ϭ 7.15, p ϭ 0.008). Further, the onestage group displayed no further mean improvement after 2 mo and steadily increasing levels of variance, although this increase was not significant. By contrast, the two-stage group mean displayed continuing improvement over the study, and, although treatment differences were not statistically significant (Wald test: p ϭ 0.409), apparently greater gains than for the one-stage group were noted.
Audiometric Minimum Masking Levels
Minimum Masking Levels, displayed in Figure 9 , demonstrated a significant difference across both groups from pretreatment to 2 mo (repeated-measures ANOVA: z ϭ 7.68, p Ͻ 0.001) and to the later time points (4 mo: z ϭ 68.7, p Ͻ 0.001; 6 mo: z ϭ 5.71 p Ͻ 0.001: 12 mo: z ϭ 6.06, p Ͻ 0.001). Overall improvements after 2 mo were not statistically significant, although the difference from 2 and 6 mo was significant (z ϭ 2.05, p ϭ 0.041). In terms of clinical significance, among the 30 subjects across the two groups who had MMLs of at least 5 dB SL at pretherapy, 70% had MML reductions of at least 5 dB after 6 mo of treatment. These improvements were more consistent in the two-stage group (78%) than in the one-stage group (58%). Inter-group differences were not statistically significant.
Loudness Discomfort Levels
Loudness Discomfort Level measurements at 0.5, 1, 2, 4, and 6 kHz for each subject's lowest LDL ear at each frequency were averaged and the mean determined ( Figure 10) . These means reveal a gradual but clinically significant improvement in tolerance of loud sounds over the course of treatment in both groups. The apparent statistical relation between LDL scores, treatment group, and month is complicated by the fact that LDL scores are lower in the two-stage group for every time interval except between 6 and 12 mo ( Figure 10 ). The reversal for the last interval is significant (Wald test based on repeated-measures ANOVA results: 2 4 ϭ 12.26, p Ͻ 0.016). However, before that, inter-treatment group differences are not significant (Wald test: 2 3 ϭ 5.86, p ϭ 0.119). Ignoring the final time interval, improvements in LDL scores were statistically significant across the treatment groups from pretreatment to 2 mo (repeated-measures ANOVA z ϭ 58.4, p Ͻ 0.001), from 2 mo to 6 (z ϭ 4.6, p Ͻ 0.001), and to 12 mo (z ϭ 4.56, p Ͻ 0.001). From 2 to 4 mo, the difference was not significant (z ϭ 0.70, p ϭ 0.490). Up to 6 mo, inter-treatment group differences were not statistically significant. At 12 mo, among the 23 subjects who displayed decreased sound tolerance (mean LDLs Ͻ85 db HL) before treatment, 78% reported LDL improvements of at least 5 dB.
These improvements were more consistent in the twostage group (85%) than in the one-stage group (70%).
Relation Between Reported Usage and Benefits Achieved
At each time interval through treatment, subjects were asked to estimate their daily usage of the acoustic treatment over the prior period. To assess any relation between reported usage and clinical outcomes, the pooled 35 subjects were assigned into one of three "usage bands": low users were those whose reported usage was between 0 and 1.5 hr per day [at 2 mo, 1.1 hr per day mean reported usage (N ϭ 11); at 4 mo, 1.1 hr per day mean reported usage (N ϭ 11)], moderate users between 1.6 and 2 hr per day [at 2 mo, 2.0 hr per day mean usage (N ϭ 13); at 4 mo, 1.9 hr per day mean reported usage (N ϭ 13)], and high users more than 2 hr per day [at 2 mo, 3.4 hr per day mean usage (N ϭ 11); at 4 mo, 2.8 hr per day mean reported usage (N ϭ 11)]. Figure 11 displays the clinical outcomes achieved for low, moderate, and high users after 4 mo. Illus- 
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EAR & HEARING / APRIL 2007 trated are the mean improvement in TRQ score (and standard deviation) and the consistency of improvement in TRQ (defined as the proportion of subjects in each usage band reporting at least a 40% improvement). It reveals a clear relation between clinical outcomes observed and average daily device usage in the early stages of treatment, which was statistically significant (z ϭ 5.53, p ϭ 0.009). If individual usage levels are used to predict percent change in TRQ over 4 mo, based on linear regression, there is a significant positive relation (t(33) ϭ 3.64, p ϭ 0.001).
Benefit Ratings
After 12 mo of treatment, subjects were asked to rate the degree of benefit they perceived on eight different aspects of their tinnitus experience and general well-being. Of the 35 trial participants, one did not complete this questionnaire because he had been lost to follow-up before the 12-month review; two others were inadvertently provided with a different version of this questionnaire in which some questions were worded differently and so were excluded. Figure 12 displays the proportion of the 32 respondents who had indicated the various degrees of benefit on each question. It reveals that a high proportion of subjects reported that the benefits they felt they had achieved were at least moderate in degree in their ability to cope with their tinnitus, their sense of control over their tinnitus, relief from their tinnitus, their ability to get a good night's sleep or relax, and the extent to which their general well-being had improved. There were no statistically significant differences in these ratings between treatment groups for any of the outcomes.
User Satisfaction
In the post-treatment questionnaire administered after 12 mo, subjects were asked whether they found the treatment pleasant to listen to: 97% (31/32) indi- Fig. 11 . Relation between reported usage and clinical improvement after 4 mo. Subjects were categorized into three "usage bands" according to their reported estimated average daily usage over the first 4 mo of treatment: those whose reported usage was between 0 and 1.5 hr per day, between 1.6 and 2 hr per day, or above 2 hr per day. Mean improvement in TRQ score and standard deviation (both expressed as a percentage of mean pretreatment TRQ (a) and consistency of improvement on TRQ (expressed as the proportion of total subjects in each group that reported a TRQ improvement of at least 40%) (b) are displayed as solid bars, with error bars corresponding to 1 standard deviation. Fig. 12. Benefit ratings. On each dimension of benefit, subjects were asked to indicate whether they felt that benefit applied to them to a small, moderate, or large degree or not at all. These are displayed as the percentages of all respondents that indicated each level of benefit. cated "yes." In response to a question asking whether they would recommend the treatment to others, 97% (33/34) indicated "yes." These responses indicate that subjects were generally satisfied with the treatment and the acoustic stimulus provided as part of it.
DISCUSSION
Impact of Customization on Listening Volume and Stimulus Masking Levels
A core component of the Neuromonics Tinnitus Treatment is an acoustic stimulus (comprising a combination of music and noise) that is customized for each individual's audiometric profile using proprietary, patented algorithms. Measurements of each subject's Stimulus Masking Level using the same acoustic stimuli with and without processing provided a clear demonstration of the benefits provided by this customization process. It allowed subjects to cover up their tinnitus perception at a listening volume that was on average 16 dB lower for the stimulus used for the two-stage group. This represents a substantial reduction, given that 6 dB corresponds to an approximate doubling of intensity. It also represents a substantial advance over previously available approaches, such as the use of broadband noise. Other researchers (e.g., Sheldrake, Coles & Foster, 1995) have observed that the broadband noise commonly used in Tinnitus Retraining Therapy (TRT) (Jastreboff & Hazell, 2004) does not in practice provide broadband stimulation when patients' hearing loss is considered and that this may be a contributing factor to the extended time frame required for that approach (Baguley, Beynon & Thornton, 1997) . Customization is especially beneficial with the use of music as an acoustic stimulus, given its highly dynamic nature and low-frequency bias. In the absence of customization, these factors typically result in uncomfortably loud listening volumes before a high level of interaction with tinnitus perception can be achieved.
Clinical Efficacy of the Neuromonics Tinnitus Treatment
Significant improvements were reported by a high proportion of subjects on all key measures, in particular during the early months of receiving the Neuromonics Tinnitus Treatment. On the primary measure of tinnitus-related distress, the TRQ, as well as on tinnitus awareness, large improvements were evident quickly, i.e., after 2 mo. More modest additional changes were observed in mean scores up to 6 and 12 mo, although no statistical significance was found in the case of further TRQ improvements. This translates into a large, positive impact on the lifestyle effects of tinnitus as a result of the Neuromonics Tinnitus Treatment. The overall success rate was 91% of all subjects after 6 mo of treatment, where success is defined as an improvement of at least 40% on this measure. Mean improvement across the two treatment groups (35 subjects) on this measure was 65% at 6 mo. As the main changes were noted in the early stages, it may be possible that the same level of improvement can be achieved in a shorter treatment time.
It is worth noting that progressive reductions in the percentage of time that subjects reported being aware of their tinnitus occurred while the mean usage of the device progressively decreased. This can be construed as another indication that there is a large, permanent treatment effect rather than just benefit obtained from gaining relief from the tinnitus at the specific times the processor was being used.
Compared with the TRQ and awareness measures, the MMLs and LDLs displayed more gradual, progressive improvement over 12 mo. This may reflect a more gradual process of neuro-plastic change. Overall improvements ultimately achieved were substantial on both of these measures: for the two-stage group, mean MML improvement at 12 mo was 12.1 dB, and mean LDL improvement was 10.4 dB.
These outcomes compare favorably with published results from alternative approaches that combine counseling with some form of acoustic therapy, such as TRT, tinnitus masking, or cognitive behavioral therapy with noise generators. In a recently published study (Henry, Schechter, Loovis, et al., 2005) , among the 90% of subjects who completed treatment, 19% of those provided with tinnitus masking and 29% of those undertaking TRT had experienced "clinically significant improvement" after 6 mo, 30% and 55%, respectively, after 12 mo, and 33% and 74%, respectively, after 18 mo. Clinically significant improvement in that study was defined as a reduction in total THI score of at least 20 points, among those clients whose pretreatment score exceeded 20 points. Mean group improvements on this measure were approximately 17% for the tinnitus masking group and 26% for the TRT group after 6 mo, 21% and 42%, respectively, after 12 mo, and 22% and 57%, respectively, after 18 mo. The many differences between these studies, for example, the use of different primary measures (TRQ versus THI) as well as differences in the patient populations (veterans versus non-veterans), limit the extent to which direct comparisons can be drawn between them. This notwithstanding, improvements observed with the Neuromonics Tinnitus Treatment were larger and were achieved more rapidly and more consistently. Furthermore, the patient populations appear comparable specifically with respect to the mean level of tinnitus severity, when a TRQ/THI score transform is applied. Improvements reported in the present study with the Neuromonics Tinnitus Treatment were
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EAR & HEARING / APRIL 2007 also greater than those reported recently for cognitive behavioral therapy, with or without noise generators (Hiller & Haerkotter, 2005) . In that study, mean improvements in tinnitus disturbance, as measured using the Tinnitus Questionnaire, were 41% and 31% for subjects with moderate and severe disturbance before treatment, respectively, after 6 mo, and 38% and 35%, respectively, after 18 mo. Improvements in MML reported in the present study, which averaged 11 dB at 6 mo, compare favorably with published results for TRT. For example, in a retrospective study of 382 patients, MML improvements averaged 5 dB (Jastreboff, Hazell & Graham, 1994) . Improvements in LDLs are comparable with improvements reported for TRT (e.g., Gold, Formby, & Frederick, et al., 2002) . The apparently greater efficiency of the Neuromonics Tinnitus Treatment is believed to be primarily the result of the nature of the acoustic stimulus used. This view is consistent with recently published animal studies that demonstrated that tonotopic reorganization associated with noise-induced, high-frequency hearing loss was preventable through administration of an acoustic stimulus specific to the regions of hearing loss (Norena & Eggermont, 2005) . Lower frequency sound enrichment was found to be not effective in this regard. In light of these results, those researchers recommended that tinnitus treatments should ideally provide acoustic signals that are tailored to correct for hearing loss, so that stimulation is provided across the broadest possible range of neurons (Eggermont, 2005) . Consistent with this, the Neuromonics acoustic stimulus is customized for each individual's specific hearing loss profile.
Relation Between Usage and Clinical Outcomes
A relation was apparent between clinical outcomes observed and average daily device usage reported by subjects. This relation was most clearly evident in the early stages of treatment (i.e., after 2 to 4 mo). In the case of TRQ improvements, differences between usage bands were statistically significant at 4 mo. This may indicate that a "dosage effect" applies to the acoustic stimulus used in the Neuromonics Tinnitus Treatment, whereby increased usage is reflected in improved clinical outcomes, over the three-fourths to 4½-hr range of reported daily usage. It is also possible that those subjects who noticed the strongest early benefit were encouraged by their experiences to use the device more each day.
It should be noted that the device usage data were estimated and reported by subjects at the end of each time interval and are therefore subject to under-and over-estimation and under-and overreporting error. However, since all the data would be susceptible to such error to the same degree, this issue is not believed to have contributed materially to the observed relation.
Relative Efficacy of Stage-Related Variants of Neuromonics Tinnitus Treatment
Inter-group differences were not statistically significant on any of the key measures. However, there was an indication of more consistent benefit in the two-stage group (in which an initial 2-month stage, during which tinnitus perception was covered up to a high degree, was followed by a 4-month stage of intermittent tinnitus perception) relative to the onestage group (in which subjects experienced intermittent tinnitus perception throughout treatment).
Based on these outcomes, it would appear that an initial phase, during which tinnitus perception is covered up to a high degree, provides an added initial benefit for at least some patients. It is not clear whether this may be the result of the additional stimulation of the auditory system provided under the two-stage protocol or the greater degree of initial relief from the tinnitus perception and hence greater deconditioning of the limbic system-mediated secondary reaction, or a combination of these factors.
CONCLUSION
This study found that the Neuromonics Tinnitus Treatment provides rapid and profound improvements to the severity of tinnitus symptoms and their effect on the patient's quality of life. This was a consistent effect, provided by a treatment that patients reported as being pleasant to use. Both of the stage-based variations of the treatment that were tested in this study were shown to be successful in achieving these outcomes.
